Identification and Characterization of Real-World Evidence Presented on Brand Websites for the **Top 20 Medicines with the Highest CMS Expenditure**

Ashik Jayakumar, Daniel Gratie, Lorie Mody, Richard H Stanford

AESARA, Inc., Chapel Hill, NC, USA

BACKGROUND



Real-world evidence (RWE) allows for an increased understanding of drug effectiveness, safety, and impact on patients in clinical settings



Pharmaceutical companies communicate RWE through channels such as brand websites to highlight acceptable RWE to appropriate stakeholders



There is an interest to understand the extent to which RWE is being used by pharmaceutical companies to communicate the value beyond clinical trial data on the brand websites



The interest for evidence communication is especially high in the top 20 Centers for Medicare & Medicaid Services (CMS) spending medicines

OBJECTIVE

To identify and categorize how often and what kind of RWE is being communicated proactively on brand websites for the top 20 CMS spending medicines

METHODS

The top 20 CMS spending medicines were identified using CMS.gov¹

The patient and healthcare professional (HCP) brand websites for each medicine were identified (Figure 1)

Within these websites, keyword searches were conducted to identify whether RWE was communicated on the brand websites

The number of brand websites presenting RWE was quantified and the information was characterized

Figure 1: Search strategy to identify the top 20 CMS spending drugs and RWE communicated on brand websites




Table 1 and Figure 2 summarize the information conveyed on brand websites regarding RWE

Table 1: RWE communication on brand websites

Table I. RWL COMMUNICATION ON DIANU WEDSITES									
Product	(rivaro	elto® xaban) ed Nov-11	Humira® (adalimumab) Approved Feb – 21	Trelegy® (fluticasone/umeclidinium/ vilanterol) Approved Sep – 21	Ibrance® (palbociclib) Approved Feb 2015	Entresto ® (sacubitril/valsartan) Approved July 2015			
Manufacturer	Bayer		AbbVie	GSK	Pfizer	Novartis			
Therapeutic Area	Cardiovascular		Gastroenterology	Respiratory	Oncology	Cardiovascular			
RWE Endpoint Referenced on Website	Rates of stroke or systemic embolism in obese patients	DVT incidence	Safety	Reduction in exacerbations in early vs delayed initiation following first COPD exacerbation	Comparative effectiveness	QoL			
Publication Type (Date)	Manuscript (2019)	Manuscript (2019)	Abstract (2018) Poster (2018) Data on File	Manuscript (2022)	Manuscript (2022) DOF	Data on File			
RWE Study Type	Claims analysis	Non-interventional open label cohort study	Ongoing Registry Study	Claims analysis	Claims analysis	Registry Study			
RWE Study Endpoints	Composite risk of ischemic stroke and systemic embolism, bleed risk, HCRU, costs in obese patients	AEs, including bleeding and thromboembolic events, Crude and adjusted incidences were calculated	 Registry treatment-emergent: A. AEs B. Serious infections by 2 + patients in either group C. Malignancy 	 A. Rate of COPD exacerbations B. Time to first overall, moderate, and severe COPD exacerbations C. Median time to exacerbation 	A. Real-world PFSB. OS	A. KCCQ-12 (HRQoL Survey)			
Active Comparator	Comparator (vs warfarin)	Comparator (vs SOC)	Non-active (single-arm)	Not applicable	Comparator (vs Al monotherapy)	Non-active (single arm)			
ClinicalTrials.gov		NCT00831714 (Not a PAS study)	NCT01848561 (Not a PAS study)						
Study Included in Package Insert	No	No	No	No	No	No			
Clinical Trial Endpoint	Rates of stroke or systemic embolism	DVT incidence	Clinical Remission & Safety (serious AEs, infection, malignancy)	Rate of moderate or severe COPD exacerbations	PFS ORR OS	CV death Hospitalizations			

Figure 2: RWE communication on brand websites

C	5 of the top 20 MS spending drugs use RWE on the brand websites all of which were exclusively on HCP facing portals	RW proo RW med mar
	Therapeutic areas represented Cardiovascular (2), respiratory (1), gastroenterology (1), oncology (1)	wet
	Study types Product RWE communication was conducted via multiple types of studies: Claims analysis, registries, non-interventional open-label study	FU Unc
	Clinical trial endpoint alignment 5/6 (83%) RWE endpoints aligned with endpoints found in the approved product label	con mar
	Population groups Overall, RWE population groups match that of pivotal clinical trials. In addition, RWE has been used to provide additional information on patient subpopulations	Fur ave com

ABBREVIATIONS

AE	adverse event
CMS	Centers for Medicare & Medicaidand
CV	cardiovascular
COPD	chronic obstructive pulmonary disease
DOF	data on file
DVT	deep vein thrombosis
HCP	healthcare profession
HCRU	healthcare resource use
KCCQ	Kansas City Cardiomyopathy Questionnaire
PFS	progression-free surviva
QoL	quality of life
RWE	real-world evidence
SOC	standard of care
PAS	post-approval study

REFERENCES

1. Centers for Medicare & Medicaid Services (CMS). Medicare Part D Spending by Drug 2021. https://data. cms.gov/summary-statistics-on-use-and-payments/ medicare-medicaid-spending-by-drug/medicare-partd-spending-by-drug/data

AC	
Ker)
gra	ľ

CONCLUSION

VE is being utilized by manufacturers to highlight oduct information beyond clinical trial data

VE is underutilized for the top CMS spending edicines, presenting an opportunity for anufacturers to highlight and leverage RWE on brand ebsites

JTURE DIRECTION/ NEXT STEPS:

nderstand the barriers and hesitations to mmunicating RWE on brand websites by anufacturers

irther expand upon and understand various venues available for manufacturers to proactively mmunicate RWE on brand websites

CKNOWLEDGEMENT nneth W. K. Wu developed the aphics for this poster.

FINANCIAL SUPPORT

This research study was sponsored by AESARA.

CONTACT INFORMATION

Ashik Jayakumar PharmD Postdoctoral Fellow, Health Outcomes and Market Access UNC Eshelman School of Pharmacy, AESARA Phone: +1 919 656 3377 E-mail: ashik.jayakumar@aesara.com Presented at: ISPOR International Conference; May 5-8, 2024; Atlanta, GA, USA



poster her aesara.com